{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T16:48:25Z","timestamp":1783183705425,"version":"3.54.6"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computer Methods and Programs in Biomedicine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.cmpb.2023.107968","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T23:06:08Z","timestamp":1701817568000},"page":"107968","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["A model of subcutaneous pramlintide pharmacokinetics and its effect on gastric emptying: Proof-of-concept based on populational data"],"prefix":"10.1016","volume":"244","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2923-6618","authenticated-orcid":false,"given":"Clara","family":"Furi\u00f3-Novejarque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6228-5190","authenticated-orcid":false,"given":"Iv\u00e1n","family":"Sala-Mira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5659-1212","authenticated-orcid":false,"given":"Jos\u00e9-Luis","family":"D\u00edez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7286-3719","authenticated-orcid":false,"given":"Jorge","family":"Bondia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmpb.2023.107968_br0010","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1046\/j.1464-5491.2002.00657_1.x","article-title":"Anti-diabetogenic effect of the human letters amylin analogue, pramlintide, in type 1 diabetes is not mediated by GLP-1","volume":"19","author":"Ahr\u00e9n","year":"2002","journal-title":"Diabet. Med."},{"key":"10.1016\/j.cmpb.2023.107968_br0020","author":"Amylin Pharmaceuticals"},{"key":"10.1016\/j.cmpb.2023.107968_br0030","first-page":"55","article-title":"Use of a novel triple-tracer approach to assess postprandial glucose metabolism","volume":"284","author":"Basu","year":"2003","journal-title":"Am. J. Physiol: Endocrinol. Metab."},{"key":"10.1016\/j.cmpb.2023.107968_br0040","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jpeds.2009.03.012","article-title":"Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study","volume":"155","author":"Chase","year":"2009","journal-title":"J. Pediatr."},{"key":"10.1016\/j.cmpb.2023.107968_br0050","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1093\/bioinformatics\/btr431","article-title":"GenSSI: a software toolbox for structural identifiability analysis of biological models","volume":"27","author":"Chi\u015f","year":"2011","journal-title":"Bioinformatics"},{"key":"10.1016\/j.cmpb.2023.107968_br0060","first-page":"903","article-title":"Distribution and kinetics of amylin in humans","volume":"274","author":"Clodi","year":"1998","journal-title":"Am. J. Physiol: Endocrinol. Metab."},{"key":"10.1016\/j.cmpb.2023.107968_br0070","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/j.1552-4604.1996.tb04147.x","article-title":"Pharmacokinetics and pharmacodynamics of AC137 (25,28,29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes","volume":"36","author":"Colburn","year":"1996","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.cmpb.2023.107968_br0080","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1109\/TBME.2006.883792","article-title":"A system model of oral glucose absorption: validation on gold standard data","volume":"53","author":"Dalla Man","year":"2006","journal-title":"IEEE Trans. Biomed. Eng."},{"key":"10.1016\/j.cmpb.2023.107968_br0090","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/1932296813514502","article-title":"The UVA\/PADOVA type 1 diabetes simulator: new features","volume":"8","author":"Dalla Man","year":"2014","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.cmpb.2023.107968_br0100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/17446651.2.1.9","article-title":"Pramlintide acetate in the treatment of type 2 and type 1 diabetes mellitus","volume":"2","author":"Edelman","year":"2007","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"10.1016\/j.cmpb.2023.107968_br0110","first-page":"1","article-title":"Nonlinear mixed effects modeling of glucagon kinetics in healthy subjects","author":"Faggionato","year":"2023","journal-title":"IEEE Trans. Biomed. Eng."},{"key":"10.1016\/j.cmpb.2023.107968_br0120","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1208\/s12248-012-9409-7","article-title":"Study reanalysis using a mechanism-based pharmacokinetic\/pharmacodynamic model of pramlintide in subjects with type 1 diabetes","volume":"15","author":"Fang","year":"2013","journal-title":"AAPS J."},{"key":"10.1016\/j.cmpb.2023.107968_br0130","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1111\/dom.13445","article-title":"Impact of macronutrient content of meals on postprandial glucose control in the context of closed-loop insulin delivery: a randomized cross-over study","volume":"20","author":"Gingras","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.cmpb.2023.107968_br0140","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1472-8206.2008.00633.x","article-title":"The Hill equation: a review of its capabilities in pharmacological modelling","volume":"22","author":"Goutelle","year":"2008","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.cmpb.2023.107968_br0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nmo.13546","article-title":"Advances in the physiology of gastric emptying","volume":"31","author":"Goyal","year":"2019","journal-title":"Neurogastroenterol. Motil."},{"key":"10.1016\/j.cmpb.2023.107968_br0160","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2337\/dc19-1922","article-title":"A novel dual-hormone insulin-and-pramlintide artificial pancreas for type 1 diabetes: a randomized controlled crossover trial","volume":"43","author":"Haidar","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmpb.2023.107968_br0170","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1399-5448.2008.00490.x","article-title":"Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus","volume":"10","author":"Hassan","year":"2009","journal-title":"Pediatr. Diabetes"},{"key":"10.1016\/j.cmpb.2023.107968_br0180","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1124\/pr.115.010629","article-title":"Amylin: pharmacology, physiology, and clinical potential","volume":"67","author":"Hay","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.cmpb.2023.107968_br0190","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1210\/jc.2015-3952","article-title":"Effect of pramlintide on postprandial glucose fluxes in type 1 diabetes","volume":"101","author":"Hinshaw","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cmpb.2023.107968_br0200","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1088\/0967-3334\/25\/4\/010","article-title":"Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes","volume":"25","author":"Hovorka","year":"2004","journal-title":"Physiol. Meas."},{"key":"10.1016\/j.cmpb.2023.107968_br0210","doi-asserted-by":"crossref","first-page":"689","DOI":"10.4158\/EP09044.ORR1","article-title":"Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: observations from a pilot study","volume":"15","author":"Huffman","year":"2009","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.cmpb.2023.107968_br0220","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1177\/1932296816647976","article-title":"Adjuvant liraglutide and insulin versus insulin monotherapy in the closed-loop system in type 1 diabetes: a randomized open-labeled crossover design trial","volume":"10","author":"Ilkowitz","year":"2016","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.cmpb.2023.107968_br0230","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/BF00400683","article-title":"Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM","volume":"39","author":"Kolterman","year":"1996","journal-title":"Diabetologia"},{"key":"10.1016\/j.cmpb.2023.107968_br0240","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s001250050646","article-title":"Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM","volume":"40","author":"Kong","year":"1997","journal-title":"Diabetologia"},{"key":"10.1016\/j.cmpb.2023.107968_br0250","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s001250050949","article-title":"The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM","volume":"41","author":"Kong","year":"1998","journal-title":"Diabetologia"},{"key":"10.1016\/j.cmpb.2023.107968_br0260","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2337\/dc21-2304","article-title":"Low-dose dasiglucagon versus oral glucose for prevention of insulin-induced hypoglycemia in people with type 1 diabetes: a phase 2, randomized, three-arm crossover study","volume":"45","author":"Laugesen","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmpb.2023.107968_br0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.appet.2022.105965","article-title":"Creating the amylin story","volume":"172","author":"Lutz","year":"2022","journal-title":"Appetite"},{"key":"10.1016\/j.cmpb.2023.107968_br0280","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1089\/dia.2013.0054","article-title":"In silico design of optimal ratio for co-administration of pramlintide and insulin in type 1 diabetes","volume":"15","author":"Micheletto","year":"2013","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.cmpb.2023.107968_br0290","first-page":"A-136","article-title":"A new pharmacokinetics and pharmacodynamics model of subcutaneous pramlintide infusion","volume":"25","author":"Miragall","year":"2023","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.cmpb.2023.107968_br0300","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1152\/physrev.00025.2016","article-title":"The new biology and pharmacology of glucagon","volume":"97","author":"M\u00fcller","year":"2017","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.cmpb.2023.107968_br0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11892-015-0630-5","article-title":"The role of dietary protein and fat in glycaemic control in type 1 diabetes: implications for intensive diabetes management","volume":"15","author":"Paterson","year":"2015","journal-title":"Curr. Diabetes Rep."},{"key":"10.1016\/j.cmpb.2023.107968_br0320","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1177\/1932296813517323","article-title":"A model of glucose-insulin-pramlintide pharmacokinetics and pharmacodynamics in type I diabetes","volume":"8","author":"Ramkissoon","year":"2014","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.cmpb.2023.107968_br0330","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1203\/PDR.0b013e318159af8c","article-title":"The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes","volume":"62","author":"Rodriguez","year":"2007","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.cmpb.2023.107968_br0340","unstructured":"A. Rohatgi, 2022, WebPlotDigitizer."},{"key":"10.1016\/j.cmpb.2023.107968_br0350","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2337\/dc16-0089","article-title":"Mitigating meal-related glycemic excursions in an insulin-sparing manner during closed-loop insulin delivery: the beneficial effects of adjunctive pramlintide and liraglutide","volume":"39","author":"Sherr","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmpb.2023.107968_br0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106218","article-title":"E-DES-PROT: a novel computational model to describe the effects of amino acids and protein on postprandial glucose and insulin dynamics in humans","volume":"26","author":"van Sloun","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.cmpb.2023.107968_br0370","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/dom.12789","article-title":"Glucagon in artificial pancreas systems: potential benefits and safety profile of future chronic use","volume":"19","author":"Taleb","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.cmpb.2023.107968_br0380","article-title":"Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial","author":"Thompson","year":"1996","journal-title":"Diabetes"},{"key":"10.1016\/j.cmpb.2023.107968_br0390","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1111\/dom.14447","article-title":"Alleviating carbohydrate counting with a FiASP-plus-pramlintide closed-loop delivery system (artificial pancreas): feasibility and pilot studies","volume":"23","author":"Tsoukas","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.cmpb.2023.107968_br0400","doi-asserted-by":"crossref","first-page":"e723","DOI":"10.1016\/S2589-7500(21)00139-4","article-title":"A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial","volume":"3","author":"Tsoukas","year":"2021","journal-title":"Lancet Digit. Health"},{"key":"10.1016\/j.cmpb.2023.107968_br0410","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/0378-4754(82)90645-0","article-title":"Global approaches to identifiability testing for linear and nonlinear state space models","volume":"24","author":"Walter","year":"1982","journal-title":"Math. Comput. Simul."},{"key":"10.1016\/j.cmpb.2023.107968_br0420","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.2337\/dc12-0330","article-title":"Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes","volume":"35","author":"Weinzimer","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmpb.2023.107968_br0430","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.2337\/diacare.26.11.3074","article-title":"Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes","volume":"26","author":"Weyer","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmpb.2023.107968_br0440","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2174\/1381612013397357","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control","volume":"7","author":"Weyer","year":"2001","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.cmpb.2023.107968_br0450","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1109\/TBME.2004.839639","article-title":"Insulin kinetics in type-1 diabetes: continuous and bolus delivery of rapid acting insulin","volume":"52","author":"Wilinska","year":"2005","journal-title":"IEEE Trans. Biomed. Eng."},{"key":"10.1016\/j.cmpb.2023.107968_br0460","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ecl.2019.10.008","article-title":"Role of glucagon in automated insulin delivery","volume":"49","author":"Wilson","year":"2020","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"10.1016\/j.cmpb.2023.107968_br0470","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.2337\/dc07-2446","article-title":"Impaired hyperglycemia-induced delay in gastric emptying in patients with type 1 diabetes deficient for islet amyloid polypeptide","volume":"31","author":"Woerle","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cmpb.2023.107968_br0480","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1054-3589(05)52006-4","article-title":"Inhibition of gastric emptying","volume":"52","author":"Young","year":"2005","journal-title":"Adv. Pharmacol."}],"container-title":["Computer Methods and Programs in Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016926072300634X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016926072300634X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:22:31Z","timestamp":1759206151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016926072300634X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":48,"alternative-id":["S016926072300634X"],"URL":"https:\/\/doi.org\/10.1016\/j.cmpb.2023.107968","relation":{},"ISSN":["0169-2607"],"issn-type":[{"value":"0169-2607","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A model of subcutaneous pramlintide pharmacokinetics and its effect on gastric emptying: Proof-of-concept based on populational data","name":"articletitle","label":"Article Title"},{"value":"Computer Methods and Programs in Biomedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmpb.2023.107968","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107968"}}